Biomarker
Fasting insulin
The check-engine light for your metabolism — and the one that comes on earliest. To keep your blood sugar normal, your pancreas quietly cranks out more and more insulin; that extra insulin is doing the work, and it’s measurable, often years before your glucose or HbA1c budge.1 Glucose is the smoke; insulin is the fire starting.
Two problems. First, fasting insulin is almost never on a standard panel — you have to ask for it, or order it yourself. Second, when you do get it, the lab marks it against a reference range of roughly 2–25 µIU/mL — and that range is a snapshot of a largely metabolically unhealthy population. So an 18 comes back “normal,” and you’re told everything’s fine when it isn’t.
The one thing to remember: insulin is a gauge, not a target. Watch it to catch your metabolism drifting early — but the win is fixing the metabolism, not chasing the number down for its own sake. No trial has shown that lowering the insulin number itself buys you longer life; the association with mortality is real but modest and still debated.7 Treat it as the smartest early-warning light you can put on your dashboard.
Last updated · every claim cited to a primary source
Reading your own result
You’ll get a number in µIU/mL (US labs; the same as µU/mL and mIU/L) or pmol/L (international). Here’s the part nobody tells you: “normal” and “optimal” are not the same thing. The lab’s wide range just describes the population walking through the door — and that population is mostly insulin-resistant. Metabolic-health doctors aim much lower. The 2–6 µIU/mL “optimal” target below is evidence-informed, not a guideline number (no major body publishes one) — so treat it as a direction, not a verdict.
| Fasting insulin (µIU/mL) | Where you stand |
|---|---|
| Under 6 | Optimal — the metabolic-health targetMaintain. This is where you want to be. |
| 6 to 9 | Good, but above optimalFine; nudge toward the low end if you can. |
| 9 to 13 | Above optimal — still flagged 'normal'Act on lifestyle now; add glucose for HOMA-IR. |
| 13 to 20 | Elevated — compensating hardMake a real plan; loop in a doctor. |
| Over 20 | High, even against the wide lab rangeSee a clinician. |
Punch your number in below to see where it lands against optimal — not just the lab’s wide “normal” — and add a fasting glucose to get your HOMA-IR, which catches resistance a normal glucose alone would hide.
Add it to unlock your HOMA-IR
Enter your fasting insulin to see where it lands against optimal — not just the wide “lab-normal” range. Add fasting glucose to get your HOMA-IR too.
HOMA-IR: the number behind the number
A fasting insulin on its own is informative; paired with fasting glucose it becomes HOMA-IR, the standard index of insulin resistance — insulin × glucose ÷ 405.4 Why it matters: a glucose of 95 mg/dL looks perfectly normal, but paired with an insulin of 14 it gives a HOMA-IR of 3.3 — clear insulin resistance that the glucose alone completely missed. There’s no universal cutoff, but 2.0 is a common watch line and ~2.5 the usual research threshold.5
Enter both a fasting insulin and a fasting glucose from the same draw to compute your HOMA-IR — the standard index of insulin resistance.
Should you test it — and which test?
Fasting insulin isn’t on the routine panel, so testing it is a deliberate choice. You especially want it if you:
- have central weight (a thicker waist) even at a “normal” BMI, or fatty liver
- have PCOS, or a family history of type 2 diabetes
- feel the symptoms — afternoon energy crashes, sugar cravings, brain fog, stubborn central weight — while your glucose and HbA1c keep coming back “normal”
- wear a CGM and can see your glucose but have never seen the insulin holding it down
- just want the earliest possible read on where your metabolism is heading
Which test? For almost everyone, the answer is fasting insulin plus a fasting glucose from the same draw (so you can compute HOMA-IR). Two escalations: an insulin-assayed OGTT (the “Kraft” test) can reveal a post-glucose insulin spike while your fasting number still looks fine — the earliest signal there is; and C-peptide is the one to use if you’re on injected insulin. The tool below routes you.
How to get it, and what it costs. Ask your doctor to add it to your next fasting draw, or order it direct-to-consumer for about $28 — no doctor needed. Either way, fast 8–12 hours (water only) beforehand.
Answer the two questions and we’ll point you to the right test — and the cheapest way to get it.
What actually lowers it (ranked honestly)
The good news: the levers that improve insulin sensitivity are mostly free, and they’re the same ones that improve everything else. Two axes, on purpose: tier is the all-things-considered verdict (effect weighed against cost, access, and effort); evidence grade is how solid the science is. They disagree sometimes — metformin has A-grade evidence but a B tier, because it’s a prescription aimed at at-risk groups, not a first move for a healthy optimizer.
Tier S — the master lever
Lose excess visceral fat
diabetes incidence ↓ up to 58%Almost everything else on this list is, at bottom, a way to do this. Losing fat — especially the visceral fat around your organs — is what drove the only A-grade hard outcomes here: the Diabetes Prevention Program cut new diabetes by 58% with lifestyle change,8 and DiRECT put established type 2 diabetes into remission in nearly half of people through weight loss alone.9 The honest caveat: preventing diabetes is proven; buying heart protection is not — Look AHEAD lost the weight, improved the metabolics, and still found no reduction in cardiovascular events.10 If you’re already lean, this lever isn’t yours — skip to the A-tier.
Tier A — high value, reach for these
Resistance training
HOMA-IR ↓ (d ≈ −0.25, up to −0.43)Muscle is your largest glucose sink, and building it improves insulin sensitivity independent of weight loss — a network meta-analysis puts the HOMA-IR effect around d −0.25, larger with heavier, longer training.15 Two or three sessions a week is the highest-leverage thing most desk-bound people aren’t doing.
Cut refined carbs & added sugar
HOMA-IR SMD ≈ −0.66 (varies)One of the larger single dietary levers: a meta-analysis of low-carb trials found a pooled HOMA-IR drop of about SMD −0.66.13 But be honest about the spread — it’s heterogeneous, and the advantage all but vanishes when both groups also exercise.14 You don’t need full keto; cutting refined starch, sugary drinks, and ultra-processed carbs captures most of it.
Aerobic / Zone 2 cardio
insulin sensitivity ES ≈ 0.44Roughly on par with resistance training for insulin sensitivity, and combining the two is the strongest option of all (combined training: HOMA-IR MD −0.52).15 The popular “4 × 45 min of Zone 2 a week” dose is a sensible convention, not a trial-derived prescription — the point is regular, sustained aerobic work.
Sleep 7–9 hours
↓ ~20% sensitivity after one bad nightUnderrated because it’s free. A single night of short sleep cut insulin sensitivity about 20% in healthy volunteers,17 and a week at five hours a night did the same chronically.18 These are small mechanistic studies, hence the C — but the direction is unambiguous, and you can act on it tonight.
Post-meal walks
postprandial glucose ↓A 10–15 minute walk after meals flattens the post-meal glucose spike — and three short walks beat one long one for 24-hour glucose.16 The direct fasting-insulin data is thinner (hence C), but the effort is near-zero and the metabolic logic is sound. Easiest habit on the page.
Tier B — powerful, but prescription / for the right person
GLP-1 agonists (semaglutide, tirzepatide)
large weight loss; insulin ↓For someone with real obesity, these produce weight loss — and insulin improvement — that lifestyle often can’t match, and SELECT showed a 20% drop in cardiovascular events.12 The grade is A for that population (SELECT enrolled people with prior heart disease); for a lean primary-prevention reader it’s a B-grade extrapolation. Lift while you take it — some of the loss is muscle. Roughly $1,000+/month branded.
Metformin
diabetes incidence ↓ 31%Cheap, old, and proven: it cut new diabetes 31% in the DPP8 and all-cause mortality 36% in overweight type 2 diabetics in UKPDS 34.11 Tier B only because it’s a prescription and that hard-outcome evidence sits in at-risk groups, not healthy people chasing an optimal number. A reasonable conversation if you’re prediabetic or have PCOS.
Tier C — defensible, but thin or niche
Berberine
fasting insulin ↓ ~2.4; HOMA-IR ↓ ~0.85Don’t dismiss it: the meta-analytic HOMA-IR effect (−0.85) is genuinely meaningful, bigger than most supplements manage.19 The catch isn’t the effect size — it’s that the trials are in patients, product quality varies wildly between bottles, there are no hard-outcome data, and the safety record is far thinner than metformin’s. A real add-on, not “nature’s metformin.”
Myo-inositol — PCOS only
insulin / HOMA-IR ↓ (low certainty)A reasonable, low-risk option in PCOS, where insulin resistance is common — but be straight about the evidence: the synthesis behind the 2023 International PCOS Guideline rated the metabolic data “limited and inconclusive.”20 It’s a conditional, shared-decision recommendation, and there’s little reason to expect it to help insulin outside PCOS.
Tier D — popular, but the number doesn't move
Apple cider vinegar
fasting insulin unchanged / slightly ↑The internet’s favourite metabolic hack does blunt a single meal’s glucose — but it doesn’t fix your baseline. A 2025 meta-analysis found HOMA-IR unchanged and fasting insulin actually rose slightly.21 Fine as a condiment; useless as an insulin intervention.
Cinnamon, chromium, exogenous ketones
weak / inconsistentCinnamon’s effect on fasting insulin is inconsistent; chromium helps mainly if you’re deficient, and most people aren’t; exogenous ketones raise blood ketones without improving insulin sensitivity. Spend the money and attention on the A-tier instead.
Grades: A replicated hard-outcome trials · B solid biomarker/surrogate trials · C small or mechanistic · D the claim doesn’t hold up. Tier (recommendation) and grade (evidence) are different axes on purpose.
If you have PCOS
This is the marker that earns its keep. Insulin resistance is present in roughly 50–70% of PCOS — closer to 70–95% with obesity, 30–50% when lean — and it often drives the symptoms.22 A normal glucose can hide it, so fasting insulin and HOMA-IR add real information here that a standard glucose test misses. On the treatment side, myo-inositol is a reasonable low-risk option, but be clear-eyed: the guideline-grade evidence for its metabolic effect is low-certainty,20 and metformin has the stronger track record. Test, then decide with a clinician.
What we looked into and ruled out
The popular hacks, and why they don’t earn a place in the plan above.
Confirm it’s working
Made a change — cut the refined carbs, started lifting, fixed your sleep? Insulin responds faster than HbA1c. Because you’re measuring today’s state rather than a 90-day average, meaningful movement shows up in weeks, not the three months A1c needs. Retest every 3–6 months while you’re actively changing things — and always on the same lab, fasted. The one discipline that matters: don’t over-read a single point. Assays aren’t standardized and your own level swings 20–40% between draws, so a true 9 can read anywhere from 6 to 12.3 Trust the trend across two or three draws, not the decimals on any one.
Common questions
References
- 1.Thomas et al. — hyperinsulinemia as an early marker of metabolic dysfunction (review): insulin oversecretes to hold glucose normal, often years before glucose itself moves
- 2.Crofts et al. 2023 (Front Clin Diabetes Healthcare) — 30.5% of 1,313 young adults (16–25) had hyperinsulinemia despite normal glucose and HbA1c (cross-sectional)
- 3.Insulin assay standardization (Clin Chem Lab Med 2025, PMID 40802520) — 12 immunoassays from 9 manufacturers ranged −298 to +303 pmol/L vs the reference method; only one agreed
- 4.Matthews DR et al. 1985 (Diabetologia) — the original HOMA model: HOMA-IR = fasting insulin × fasting glucose ÷ 405 (mg/dL)
- 5.HOMA-IR cutoff overview — no universal threshold; 2.0–2.5 are the common values, NHANES research cutoff ~2.5, lower in Asian populations
- 6.Insulin unit conversion (µIU/mL ↔ pmol/L) — both 6.0 and 6.945 factors are in circulation; the correct one is assay-dependent
- 7.Gast et al. 2017 (Biosci Rep) — meta-analysis (7 studies, 26,976 non-diabetic adults): fasting insulin's link to all-cause mortality is modest (RR ~1.13) and the independent role of hyperinsulinemia 'remains controversial'
- 8.Diabetes Prevention Program (NIDDK) — intensive lifestyle cut new diabetes 58%, metformin 31%, vs placebo in prediabetes
- 9.DiRECT (Lancet Diabetes Endocrinol 2019, PMID 30852132) — a weight-loss programme put type 2 diabetes into remission in 46% at 1 year, 36% at 2 years
- 10.Look AHEAD (NEJM 2013, PMID 23796131) — intensive lifestyle + weight loss did NOT cut cardiovascular events in type 2 diabetes (HR 0.95, p=0.51): the number moved, outcomes didn't
- 11.UKPDS 34 (Lancet 1998, PMID 9742977) — metformin cut all-cause mortality 36% in overweight, newly-diagnosed type 2 diabetes
- 12.SELECT (NEJM 2023) — semaglutide cut major cardiovascular events 20% in overweight/obese adults with prior CVD and no diabetes
- 13.Low-carbohydrate diet & HOMA-IR meta-analysis (8 RCTs, n=327): pooled SMD −0.66 — real but heterogeneous
- 14.Low-carb + exercise vs higher-carb + exercise (Diabetes Obes Metab 2026) — HOMA-IR difference null (MD −0.17, ns) once both groups exercised
- 15.Exercise & insulin sensitivity — network meta-analysis (Front Endocrinol 2025): resistance training d≈−0.25, aerobic ES≈0.44, combined the strongest (HOMA-IR MD −0.52)
- 16.Post-meal walking & postprandial glycemia (systematic review/meta-analysis) — three 10-minute walks beat one 30-minute walk for 24-hour glucose
- 17.Donga et al. 2010 (JCEM) — a single night of partial sleep deprivation reduced insulin sensitivity ~20% in healthy people
- 18.Buxton et al. 2010 (Diabetes, PMID 20585000) — one week at 5 hours/night reduced insulin sensitivity
- 19.Berberine glycemic meta-analysis (J Nutr 2023) — fasting insulin −2.36 µIU/mL (11 RCTs), HOMA-IR −0.85 (12 RCTs), in patient populations
- 20.Inositol for PCOS — meta-analysis informing the 2023 International PCOS Guideline (JCEM 2024): metabolic evidence rated 'limited and inconclusive', low certainty
- 21.Apple cider vinegar in type 2 diabetes — GRADE meta-analysis (Front Nutr 2025): fasting insulin rose slightly (+2.06 µIU/mL, p=0.025) and HOMA-IR was unchanged, though single-meal glucose fell
- 22.PCOS & insulin resistance — present in 50–70% overall (≈70–95% in obese PCOS, ≈30–50% in lean PCOS)
- 23.Physiological insulin resistance / adaptive glucose sparing on low-carb — fasting glucose can rise via gluconeogenesis while insulin stays low (benign, reversible)